Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled trial of 5-ALA phosphate + sodium ferrous citrate + zinc in asymptomatic Plasmodium carriers
jRCT1030190143Not yet recruiting
- Sponsor
- Neopharma
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial in malaria comparing 5-ALA phosphate + sodium ferrous citrate + zinc with Placebo (2 arms). Primary endpoint: Change in Plasmodium DNA levels at 3 months. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
malaria
Beyond the preview
Go deeper on jRCT1030190143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030190143.